AstraZeneca (NASDAQ: AZN) announced Friday September 4, 2026 that the FDA granted accelerated approval to Etcamah (camizestrant, an oral selective estrogen receptor degrader) in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone-receptor-positive HER2-negative locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor plus CDK4/6 inhibitor therapy. FDA also approved the Guardant360 CDx blood-based next-generation sequencing assay as a companion diagnostic to identify ESR1-mutant patients. Approval was based on the Phase 3 SERENA-6 trial that documented a 56% reduction in disease progression or death versus continued standard-of-care aromatase inhibitor plus CDK4/6 inhibitor treatment in the ESR1-mutated subgroup. SERENA-6 was presented at ASCO 2026 and simultaneously published in the New England Journal of Medicine. Etcamah becomes the first oral SERD approved for the switch-at-emergence-of-ESR1 setting, replacing the fulvestrant intramuscular injection historically used post-progression. AstraZeneca is positioning Etcamah alongside Trodelvy plus Datroway as anchors of the expanded breast-cancer franchise.
AstraZeneca (NASDAQ: AZN) and Ionis Pharmaceuticals (NASDAQ: IONS) presented Sunday August 30, 2026 at ESC Congress 2026 Munich the detailed subgroup analyses from the Phase 3 CARDIO-TTRansform trial of Wainua (eplontersen, an antisense oligonucleotide targeting transthyretin) in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). CARDIO-TTRansform did not meet its primary composite endpoint (cardiovascular mortality plus recurrent CV events through 140 weeks) versus placebo. In the prespecified subgroup analysis, patients receiving eplontersen monotherapy achieved a nominally significant hazard ratio of 0.71 versus placebo, while patients on background TTR stabilizer therapy (tafamidis, Vyndaqel/Vyndamax) at baseline showed no treatment effect. The read-out complicates the silencer-plus-stabilizer commercial approach in ATTR-CM that Alnylam's HELIOS-B trial of vutrisiran validated with 28.2% mortality reduction and 32.8% CV event reduction on background tafamidis. AstraZeneca and Ionis will analyze the full dataset to inform next steps in the CARDIO-TTRansform program.
AstraZeneca (NYSE: AZN) reported Q2 2026 earnings before market open Monday July 27, 2026 with core earnings per share of $2.63 for the three months ended June 30 (+18% constant currency), beating consensus of $2.48. Revenue of $15.38 billion was in line with consensus of $15.39 billion (+5%). Analyst focus on the earnings call centered on the pipeline update: elecoglipron, the oral small-molecule GLP-1 receptor agonist AstraZeneca in-licensed and advanced through Phase 2 VISTA and SOLSTICE (positive data at ADA 2026 Scientific Sessions in June), has moved into a full Phase 3 program in Q2 2026. The Phase 3 program includes the EMBOLD trials in adults with obesity or overweight (with and without type 2 diabetes), the ELUMINATE trials in adults with type 2 diabetes (as monotherapy and in combination with dapagliflozin), and long-term cardiovascular and kidney outcome trials. AstraZeneca is now the third major sponsor competing with Novo Nordisk and Eli Lilly for the oral GLP-1 market alongside oral semaglutide/Ozempic and orforglipron (Foundayo, FDA-approved April 2026). AstraZeneca separately revised the peak sales projection for tozorakimab (experimental respiratory treatment) to above $5 billion from the previous $3 billion estimate. AZN shares rose approximately 1.7% in London Monday morning trading.